|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0001779,
umls-concept:C0003241,
umls-concept:C0021403,
umls-concept:C0032594,
umls-concept:C0036043,
umls-concept:C0038410,
umls-concept:C0042210,
umls-concept:C0178602,
umls-concept:C0305065,
umls-concept:C0521115,
umls-concept:C0546816,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2713304,
umls-concept:C2911692
|
|
pubmed:dateCreated |
1981-11-22
|
|
pubmed:abstractText |
Contemporary 14-valent pneumococcal polysaccharide vaccine was first licensed in 1977 in the United States, where about four million doses of vaccine have been distributed to date. The vaccine induces excellent antibody responses in elderly persons as well as in young adults. The antigen content of the vaccine is 50 microgram of each serotype of polysaccharide per dose, and lower titers of antibody are induced when the dose is reduced to 25 or 12.5 microgram of antigen. Adverse reactions are usually mild and consist principally of local erythema and induration at the injection site, with mild fever in a small proportion of subjects. Antibody persists well for at least four years, and it is expected that immunity will last for at least 5 years after vaccination. Local and systemic reactions to the vaccine may be greater when a second dose of vaccine is administered within three years after the initial dose, and this reactivity appears to be due to a Arthus-like response that results from local formation of antigen-antibody complexes. Pneumococcal and influenza vaccines can be injected simultaneously into separate sites without impairment of antibody responses to either vaccine; this feature should facilitate administration of these two vaccines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0162-0886
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3 Suppl
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
S31-42
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7025159-Adult,
pubmed-meshheading:7025159-Aged,
pubmed-meshheading:7025159-Antibodies, Bacterial,
pubmed-meshheading:7025159-Antibody Formation,
pubmed-meshheading:7025159-Antigen-Antibody Complex,
pubmed-meshheading:7025159-Antigens, Bacterial,
pubmed-meshheading:7025159-Bacterial Vaccines,
pubmed-meshheading:7025159-Female,
pubmed-meshheading:7025159-Humans,
pubmed-meshheading:7025159-Immunization, Secondary,
pubmed-meshheading:7025159-Influenza Vaccines,
pubmed-meshheading:7025159-Male,
pubmed-meshheading:7025159-Pneumococcal Infections,
pubmed-meshheading:7025159-Pneumococcal Vaccines,
pubmed-meshheading:7025159-Polysaccharides, Bacterial,
pubmed-meshheading:7025159-Radioimmunoassay,
pubmed-meshheading:7025159-Serotyping,
pubmed-meshheading:7025159-Streptococcus pneumoniae,
pubmed-meshheading:7025159-Time Factors,
pubmed-meshheading:7025159-Vaccination
|
|
pubmed:articleTitle |
Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.
|
|
pubmed:publicationType |
Journal Article,
Review
|
